Junshi Biological re -submits Tripley monoclonal anti -resistance to treat nasopharyngeal carcinoma biological products permits for FDA acceptance
On July 7, Capital State learned that the Science and Technology Board Corporation (688180.SH) voluntarily disclosed the announcement on re -submission of the biological product license application fo